Multiple Sclerosis
Created:   1/26/2010
Contains:  96 items

Creator: Jamie Talan
Duration: 9:15
Philip L. De Jager, MD, PhD, associate professor of neurology at Harvard University, describes the investigation that unraveled two distinct RNA profiles for MS patients, reflecting different levels of disease activity.
Creator: Neurology Today
Duration: 3:14
Journal: Neurology Today
ONO-4641, an investigational oral drug, reduced the number of lesions detected by MRI in people with relapsing remitting multiple sclerosis (RRMS) — the primary outcome for the phase 2b Drug Research EvaluAtion for MS (DreaMS) trial. Here, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the growing interest in these oral and increasingly expensive MS drugs.
For the full-text article, see the June 7 issue of Neurology Today.